OBiO Tech(SH:688238)2023-12-18 08:42Group 1: Investor Relations Activities - The company engaged in multiple investor relations activities, including specific object research, media interviews, and performance briefings, from November 24 to December 6, 2023 [1][2][3][4] - Participants included various securities firms and investment funds such as Haitong Securities, Jiashi Fund, and Guohai Securities [1] Group 2: R&D Investment and Performance - In the first three quarters of 2023, the company's R&D expenditure reached CNY 38.58 million, a year-on-year increase of 62.47%, accounting for 28.16% of total revenue, up by 17.13 percentage points from the previous year [2] - The company has obtained a total of 23 invention patents, 6 utility model patents, and 57 domestic registered trademarks as of September 2023 [2] Group 3: Regulatory Approvals - The company successfully registered its AAV vector plasmid products with the FDA under Drug Master File (DMF) numbers 038544 and 038803 in September 2023 [2][3] Group 4: CDMO Business and Revenue Recognition - The CDMO service cycle typically ranges from 7 to 14 months, depending on the project phase and client requirements [3] - Revenue is recognized based on contract milestones and client confirmations for both CRO and CDMO services [3] Group 5: Financial Performance and Challenges - The overall gross margin has declined due to a weak external economic environment and increased operational costs, impacting revenue growth [4] - The company anticipates fluctuations in gross margin due to fixed asset investments and increasing overseas orders, which may enhance profitability in the long term [4] Group 6: International Expansion - The company is expanding its operations globally, having established a subsidiary in the U.S. and a research lab in California to enhance its capabilities in gene and cell therapy [4] - Efforts to engage overseas clients are ongoing, with initial small orders being signed as part of the market entry strategy [4]